SBFM
Sunshine Biopharma Inc. · NASDAQ
- Market cap
- $2.2M
Sunshine Biopharma Inc. (SBFM) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for SBFM, including 3 SEC filings, 1 market update and 1 press release or news item. The most recent was published Nov 13, 2026.
SBFM rankings
Financial highlights
Full financials- Revenue, TTM
- $35.37M
- Revenue growth
- -5.2%
- Net income, TTM
- -$6.17M
- Net margin
- -17.5%
- Cash
- $14.62M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks45-50%
2026-05-242026-11-15
Mix2890d
- SEC Filings13(46%)
- Market8(29%)
- Other6(21%)
- 13D/G1(4%)
Activity · 52 weeks6546 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form DEFA14A filed by Sunshine Biopharma Inc.DEFA14A - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form 10-Q filed by Sunshine Biopharma Inc.10-Q - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form DEF 14A filed by Sunshine Biopharma Inc.DEF 14A - Sunshine Biopharma Inc. (0001402328) (Filer)
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Sunshine Biopharma Inc.SCHEDULE 13G/A - Sunshine Biopharma Inc. (0001402328) (Subject)
- SECSEC Form DEF 14C filed by Sunshine Biopharma Inc.DEF 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ ListingFORT LAUDERDALE, FL / ACCESS Newswire / October 22, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced a one for twenty reverse split of its common stock, effective at market open on October 26, 2026. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The reverse stock split will reduce the Company's issued and outstanding shares of common stock from 15,219,383 to approximately 760,969.About Sunshine Biopharma Inc.Sunshine Biopharma currently has
- SECSEC Form PRE 14C filed by Sunshine Biopharma Inc.PRE 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form 8-K filed by Sunshine Biopharma Inc.8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form 8-K filed by Sunshine Biopharma Inc.8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form 424B4 filed by Sunshine Biopharma Inc.424B4 - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Announces Closing of up to $20.4 Million Public Offering$6.0 million upfront with an additional $14.4 million of potential aggregate gross proceeds upon the exercise of warrants FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the closing of its previously announced public offering made on a reasonable best efforts basis with gross proceeds to the Company of approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.The offering consisted of 10,909,082 Common Un
- NEWSSunshine Biopharma Inc. Announces Pricing of $6.0 Million Public OfferingFORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.The offering consists of 10,909,083 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series D Warr
- SECSEC Form EFFECT filed by Sunshine Biopharma Inc.EFFECT - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form S-1 filed by Sunshine Biopharma Inc.S-1 - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form DEF 14C filed by Sunshine Biopharma Inc.DEF 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care PortfolioLaunch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgeryGlobal ondansetron market projected to reach $2.98 billion by 2034, up from $1.82 billion in 2025, according to DataInteloCommercial rollout supported by Nora Pharma's established Canadian distribution network, further expanding Sunshine Biopharma's generic prescription drug portfolio FORT LAUDERDALE, FL / ACCESS Newswire / September 24, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications including drugs in the areas of oncology and antivirals, is p
- SECSEC Form PRE 14C filed by Sunshine Biopharma Inc.PRE 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling StudiesNanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activitySignificant dose-dependent suppression of pulmonary viral replication in vivoStrong oral bioavailability and preferential lung enrichment across multiple species Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activitySignificant dose-dependent suppression of pulmonary viral replication in vivoStrong oral bioavailability and preferential lung enrichment across multiple species FORT LAUDERDALE, FL / ACCESS Newswire / September 16, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medication
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Other Events8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form EFFECT filed by Sunshine Biopharma Inc.EFFECT - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form 424B3 filed by Sunshine Biopharma Inc.424B3 - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSHealth Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular ConditionsFORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®.Atenolol belongs to a class of drugs known as beta-blockers. It works by blocking the action of certain natural chemicals in the body, such as epinephrine, on the heart and blood vessels. This effect lowers the heart rate, blood pressure, and strain on the heart.Atenolol is primarily indicated for:Hypertension Manag
- SECSEC Form S-1 filed by Sunshine Biopharma Inc.S-1 - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Leadership Update8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
SBFM FAQ
9 questionsWhat does Sunshine Biopharma Inc. do?
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a...What is the latest news on SBFM?
In the last 30 days Quantisnow tracked 6 wire items for SBFM: 3 SEC filings, 1 market update, 1 press release or news item and 1 13D/G filing. The most recent was published on November 13, 2026.What is SBFM revenue?
Sunshine Biopharma Inc. (SBFM) reported $35.37M of revenue for the twelve months ended Sep 30, 2026. That is down 5.2% from the year before. Revenue for fiscal 2025 was $36.31M.Is SBFM profitable?
No. Sunshine Biopharma Inc. reported a net loss of $6.17M for the twelve months ended Sep 30, 2026.How much cash and debt does SBFM have?
Sunshine Biopharma Inc. reported $14.62M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does SBFM stock trade?
Sunshine Biopharma Inc. (SBFM) is listed on NASDAQ.What sector and industry is SBFM in?
Sunshine Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to SBFM?
Notable peers in the same industry include CNSP (CNS Pharmaceuticals Inc.), MBRX (Moleculin Biotech Inc.), PCSA (Processa Pharmaceuticals Inc.), OGEN (Oragenics Inc.). Compare SBFM side-by-side with any of them on Quantisnow.How can I track SBFM on Quantisnow?
Quantisnow aggregates Sunshine Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SBFM to receive live email and push alerts on every new disclosure.